{
    "2020-08-20": [
        [
            {
                "time": "2021-08-20",
                "original_text": "FDA approves Novartis KesimptaÂ® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis",
                "features": {
                    "keywords": [
                        "FDA",
                        "approves",
                        "Novartis",
                        "Kesimpta",
                        "ofatumumab",
                        "self-administered",
                        "B-cell therapy",
                        "relapsing multiple sclerosis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-08-20",
                "original_text": "Influencers with Andy Serwer: Dr. Dan Barouch",
                "features": {
                    "keywords": [
                        "Influencers",
                        "Andy Serwer",
                        "Dr. Dan Barouch"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}